Table 2.
Ongoing or planned clinical trials using alternative interleukin-2 dosing strategies
| Trial description | ClinicalTrials.gov identifier | Alternative IL-2 dosing |
|---|---|---|
| Vemurafenib + IL-2 and IFN | NCT 01603212 | Continuous 96-hour infusion (Phase I, doses of IL-2 vary) |
| Ipilimumab + biochemotherapy | NCT 01409174 | Continuous 96-hour infusion (Phase I, doses of IL-2 vary) |
| Adjuvant IL-2 anddacarbazine | NCT00553618 | 12 million units subcutaneous on days 1–4 monthly |
| Cellular adoptive therapy using autologous CD8+ T-cells and ipilimumab | NCT02027935* | 250,000 U/m2 subcutaneously twice daily for 14 days |
| CAR T-cell receptor targeting VEGFR2 | NCT01218867 | LD bolus 72,000 IU/kg every 8 hours, maximum 15 doses |
| TIL + LD IL-2 | NCT01883323* | 125,000 IU/kg subcutaneously for 2 weeks (2 days rest between each week) |
Note:
*
Study is not yet open to patient accrual.
Abbreviations: IFN, interferon; LD, low-dose; IL-2, interleukin-2; TIL, tumor-infiltrating lymphocyte; VEGFR 2, vascular endothelial growth factor receptor-2; CAR, chimeric antigen receptor.